Feb 4 (Reuters) - Point Therapeutics Inc said in a regulatory filing that it may file for bankruptcy protection under Chapter 11 if the merger with privately held Dara BioSciences fails and no other strategic deal is completed.
Feb 4 (Reuters) - Point Therapeutics Inc said in a regulatory filing that it may file for bankruptcy protection under Chapter 11 if the merger with privately held Dara BioSciences fails and no other strategic deal is completed.